NASDAQ:CLLS
$2.51
(
-23.01%
)
Friday, 3rd Feb 2023
Cellectis S.A. Stock Price (Quote)
| Range | Low Price | High Price | Comment |
|---|---|---|---|
| 30 days | $2.25 | $4.04 | Friday, 3rd Feb 2023 CLLS stock ended at $2.51. This is 23.01% less than the trading day before Thursday, 2nd Feb 2023. During the day the stock fluctuated 12.89% from a day low at $2.25 to a day high of $2.54. |
| 90 days | $1.83 | $4.04 | |
| 52 weeks | $1.83 | $6.04 |
Historical Cellectis S.A. prices
| Date | Open | High | Low | Close | Volume |
| 2023-02-03 | $2.26 | $2.54 | $2.25 | $2.51 | 1 855 071 |
| 2023-02-02 | $3.26 | $3.30 | $3.07 | $3.26 | 44 761 |
| 2023-02-01 | $2.96 | $3.15 | $2.96 | $3.10 | 17 943 |
| 2023-01-31 | $2.96 | $3.13 | $2.90 | $3.05 | 72 142 |
| 2023-01-30 | $3.09 | $3.09 | $2.92 | $3.01 | 20 347 |
| 2023-01-27 | $3.08 | $3.14 | $3.03 | $3.10 | 97 357 |
| 2023-01-26 | $3.17 | $3.20 | $3.06 | $3.14 | 22 247 |
| 2023-01-25 | $3.19 | $3.39 | $3.02 | $3.23 | 69 859 |
| 2023-01-24 | $3.27 | $3.36 | $3.25 | $3.34 | 52 213 |
| 2023-01-23 | $3.39 | $3.44 | $3.30 | $3.38 | 133 187 |
| 2023-01-20 | $3.05 | $3.26 | $3.01 | $3.06 | 69 800 |
| 2023-01-19 | $3.28 | $3.31 | $2.97 | $3.05 | 124 605 |
| 2023-01-18 | $3.49 | $3.54 | $3.31 | $3.33 | 96 837 |
| 2023-01-17 | $4.00 | $4.04 | $3.19 | $3.38 | 340 442 |
| 2023-01-13 | $3.89 | $3.89 | $3.74 | $3.84 | 68 300 |
| 2023-01-12 | $3.75 | $3.89 | $3.61 | $3.72 | 161 202 |
| 2023-01-11 | $3.62 | $3.95 | $3.31 | $3.56 | 251 215 |
| 2023-01-10 | $3.76 | $4.01 | $3.26 | $3.53 | 517 400 |
| 2023-01-09 | $3.16 | $3.41 | $3.04 | $3.36 | 266 337 |
| 2023-01-06 | $2.59 | $2.97 | $2.59 | $2.83 | 194 141 |
| 2023-01-05 | $2.40 | $2.60 | $2.36 | $2.56 | 127 383 |
| 2023-01-04 | $2.29 | $2.41 | $2.29 | $2.38 | 87 893 |
| 2023-01-03 | $2.27 | $2.33 | $2.22 | $2.27 | 108 352 |
| 2022-12-30 | $1.90 | $2.11 | $1.85 | $2.10 | 166 654 |
| 2022-12-29 | $1.94 | $2.08 | $1.85 | $1.95 | 237 058 |
| 2022-12-28 | $1.85 | $1.93 | $1.83 | $1.85 | 125 099 |
| 2022-12-27 | $1.98 | $2.04 | $1.83 | $1.88 | 115 887 |
| 2022-12-23 | $2.13 | $2.13 | $1.89 | $1.99 | 57 015 |
| 2022-12-22 | $2.00 | $2.06 | $1.93 | $1.97 | 119 643 |
| 2022-12-21 | $1.89 | $2.05 | $1.89 | $2.02 | 123 125 |
| 2022-12-20 | $1.91 | $2.00 | $1.91 | $1.96 | 42 985 |
| 2022-12-19 | $2.01 | $2.05 | $1.85 | $1.90 | 94 134 |
| 2022-12-16 | $2.12 | $2.25 | $2.02 | $2.03 | 718 772 |
| 2022-12-15 | $2.15 | $2.25 | $2.15 | $2.25 | 58 428 |
| 2022-12-14 | $2.16 | $2.24 | $2.13 | $2.20 | 156 839 |
| 2022-12-13 | $2.36 | $2.50 | $2.29 | $2.34 | 156 282 |
| 2022-12-12 | $2.24 | $2.35 | $2.23 | $2.23 | 94 228 |
| 2022-12-09 | $2.25 | $2.25 | $2.21 | $2.21 | 33 426 |
| 2022-12-08 | $2.16 | $2.27 | $2.16 | $2.24 | 44 459 |
| 2022-12-07 | $2.20 | $2.21 | $2.13 | $2.15 | 79 334 |
| 2022-12-06 | $2.25 | $2.29 | $2.21 | $2.21 | 28 550 |
| 2022-12-05 | $2.19 | $2.27 | $2.18 | $2.23 | 91 567 |
| 2022-12-02 | $2.16 | $2.22 | $2.15 | $2.18 | 78 329 |
| 2022-12-01 | $2.24 | $2.24 | $2.15 | $2.18 | 94 861 |
| 2022-11-30 | $2.22 | $2.25 | $2.15 | $2.20 | 73 432 |
| 2022-11-29 | $2.22 | $2.26 | $2.17 | $2.17 | 101 268 |
| 2022-11-28 | $2.41 | $2.43 | $2.22 | $2.22 | 86 737 |
| 2022-11-25 | $2.42 | $2.42 | $2.33 | $2.35 | 47 497 |
| 2022-11-23 | $2.28 | $2.51 | $2.28 | $2.50 | 155 024 |
| 2022-11-22 | $2.10 | $2.19 | $2.09 | $2.17 | 46 235 |
About Cellectis S.A.
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALL... CLLS Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
